| Outcome Measures: |
Primary: Area under the plasma concentration vs time curve from zero to infinity for total (bound and unbound) drug after single dose administration of BAY94-8862 (AUC), AUC for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Maximum total (bound and unbound) drug concentration in plasma after single dose administration of BAY94-8862 (Cmax), Cmax for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|AUC for unbound drug (AUCu), AUCu for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Cmax for unbound drug (Cmax,u), Cmax,u BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|AUC divided by dose per kg body weight (AUCnorm), AUCnorm for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|AUCnorm for unbound drug (AUCu,norm), AUCu, norm for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Cmax divided by dose per body weight (Cmax,norm), Cmax, norm for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Cmax,norm for unbound drug (Cmax,u,norm), Cmax,u,norm for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose | Secondary: Plasma renin activity (PRA), Change from baseline in plasma renin activity, Prior to dosing and 12 hours post-dose|Plasma angiotensin II, Change from baseline in plasma angiotensin II, Prior to dosing and 12 hours post-dose|Serum aldosterone, Change from baseline in serum aldosterone, Prior to dosing and 12 hours post-dose|Plasminogen activator inhibitor-1 (PAI-1), Change from baseline in PAI-1, Prior to dosing and 12 hours post-dose|Urinary volume, Change in volume of urine excreted, Prior to dosing up to 24 hours post-dose|Urinary creatinine, Change in urine creatinine concentrations, Prior to dosing up to 24 hours post-dose|Urinary electrolytes, Change in urinary electrolytes, Prior to dosing up to 24 hours post-dose|Half-life associated with the terminal slope (t½), t½ for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Fraction unbound (fu), fu for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), 1 hour and 6 hours post-dose|AUC divided by dose (AUC/D), AUC/D for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|AUC from time 0 to the last data point (AUC(0-tlast)), AUC(0-tlast) for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Cmax divided by dose (Cmax/D), Cmax/D for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Time to reach Cmax (tmax), Time to reach Cmax (in case of two identical Cmax values, the first tmax was to be used) for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Mean residence time (MRT), MRT for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Total body clearance of drug calculated after extravascular administration (CL/F), CL/F for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Total body clearance of unbound drug from plasma calculated after oral administration (apparent oral unbound clearance) (CLu/F), CLu/F for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Apparent volume of distribution during terminal phase after extravascular administration (Vz/F), Vz/F for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Amount excreted into urine from 0 to 96 h (end of urine sampling) after study drug administration (AE,ur), AE,ur for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Percent amount excreted into urine from 0 to 96 h (end of urine sampling) after study drug administration (%AE,ur), %AE,ur for BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Renal body clearance of drug (CLR), CLR of BAY94-8862 and its metabolites M1 (BAY1040818), M2 (BAY1088089) and M3 (BAY1088090), Up to 96 hours post-dose|Number of participants with adverse events, Approximately 5 weeks
|
